 |
Business strategy |
To build significant company value, we have established clinical proof-of-concept of our prime product candidate Vvax001 in a first indication. We are seeking funding for Phase III through investors and partnering. Several discussions are ongoing.
We will broaden our IPR position and pipeline by new product development and broadening the indications for our lead asset Vvax001 to treat other HPV16-related cancers.
We are open to asset licensing/acquisition, platform deals or a trade sale to a strategic partner. |
| |
|
|
